Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1150221

	registered interest
	date	16/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epidemiology: Paediatrics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his Department's policies of the research by the University of Bristol published on 16 September 2019 in Paediatric and Perinatal Epidemiology; and whether he plans update his Department's guidance as a result of that research.
	tabling member constituency	North East Hampshire
	tabling member printed	Mr Ranil Jayawardena
	uin	1075
	answer	answer is ministerial correction date of answer 21/10/2019 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors the safety of all medicines on the market in the United Kingdom. Following a recent European review of the available epidemiological data on the risk of neurodevelopmental disorders with use of paracetamol in pregnancy, the product information for paracetamol is already being updated to reflect the findings.</p><p>The MHRA has sought independent advice from its expert committees on this latest study which found an increased risk of neurocognitive effects in children born to women who took paracetamol during pregnancy. The expert committees advised that the new study adds to the existing body of evidence but does not provide any further insight into a possible causal association between in utero exposure to paracetamol and neurodevelopmental outcomes.</p><p>Patients should be advised that if necessary, paracetamol can be used during pregnancy. However, it should be used at the lowest possible dose that reduces symptoms and for the shortest time possible.</p><p>Pregnant women should speak to their doctor or midwife before taking any medicine, including paracetamol.</p><p> </p><p> </p><p> </p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 21/10/2019 15:40:50 answering member 1481 label Biography information for Ms Nadine Dorries
	tabling member	4498 label Biography information for Mr Ranil Jayawardena

1149549

	registered interest
	date	15/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Non-surgical Cosmetic Procedures: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of (a) the number of under-18s who have had cosmetic fillers and Botox injections in the last year and (b) the cost to the NHS of correcting complications and mistakes involving those procedures; and if he will make it his policy to make it illegal for under-18s to be given injecting fillers.
	tabling member constituency	North East Hampshire
	tabling member printed	Mr Ranil Jayawardena
	uin	757
	answer	answer is ministerial correction date of answer 21/10/2019 answer text <p>The Department does not hold the information requested.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care.</p><p>The Department is working with stakeholders, including professional associations, to review industry standards of practice as part of the manifesto commitment to ensure there is “effective registration and regulation of those performing cosmetic interventions”. This work includes an assessment of the health risks and psychological impact of current access arrangements to injectable cosmetic procedures by children and young people.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 21/10/2019 15:40:04 answering member 1481 label Biography information for Ms Nadine Dorries
	tabling member	4498 label Biography information for Mr Ranil Jayawardena

1148262

	registered interest
	date	03/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Children: Mental Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of trends in the number of children being given (a) therapy and (b) psychiatric medication for eco-anxiety; and what steps the Government is taking to reduce those levels.
	tabling member constituency	North East Hampshire
	tabling member printed	Mr Ranil Jayawardena
	uin	294220
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>No such assessment has been made.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 08/10/2019 10:25:50 answering member 1481 label Biography information for Ms Nadine Dorries
	tabling member	4498 label Biography information for Mr Ranil Jayawardena